Bone Scan Index as an Imaging Biomarker in Metastatic Castration-resistant Prostate Cancer: A Multicentre Study Based on Patients Treated with Abiraterone Acetate (Zytiga) in Clinical Practice  Mariana Reza, Mattias Ohlsson, Reza Kaboteh, Aseem Anand, Ingela Franck-Lissbrant, Jan-Erik Damber, Anders Widmark, Camilla Thellenberg-Karlsson, Lars Budäus, Thomas Steuber, Till Eichenauer, Per Wollmer, Lars Edenbrandt, Elin Trägårdh, Anders Bjartell  European Urology Focus  Volume 2, Issue 5, Pages 540-546 (December 2016) DOI: 10.1016/j.euf.2016.02.013 Copyright © 2016 European Association of Urology Terms and Conditions

Fig. 1 Flowchart showing distribution of the participating patients. AA=abiraterone acetate; mCRPC=metastatic castration-resistant prostate cancer. European Urology Focus 2016 2, 540-546DOI: (10.1016/j.euf.2016.02.013) Copyright © 2016 European Association of Urology Terms and Conditions

Fig. 2 Kaplan-Meier curves showing patient-survival probability stratified by Bone Scan Index (BSI) change categories at follow-up. BSI changes from baseline to follow-up were evaluated among the 104 patients studied. Patients presenting BSI change values ≤0.30 (n=54) and BSI change values >0.30 (n=50) showed significantly different survival rates during the follow-up period (p<0.001). BSI=Bone Scan Index. European Urology Focus 2016 2, 540-546DOI: (10.1016/j.euf.2016.02.013) Copyright © 2016 European Association of Urology Terms and Conditions

Fig. 3 (a) Baseline and (b) follow-up whole-body bone scans of a metastatic castration-resistant prostate cancer patient treated with abiraterone acetate. Hot spots, presented in red, represent the bone area affected by a tumour. The Bone Scan Index (BSI) change from baseline to follow-up suggests BSI progression in accordance with patient's significant BSI increase (BSI change >0.30). AA=abiraterone acetate; BSI=Bone Scan Index. European Urology Focus 2016 2, 540-546DOI: (10.1016/j.euf.2016.02.013) Copyright © 2016 European Association of Urology Terms and Conditions